-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that the biotech company Rezera (RZRA.US), which has developed an oral NLRP3 inflammatory inhibitor and has advanced the pipeline to phase III clinical trials, said on Thursday that it will suspend listing. The company previously filed for an IPO and plans to issue 16.7 million shares in the distribution range of $11-13 and raise $200 million. Pharmaceutical company GlaxoSmithKline (GSK.US), as a new investor and associated party, promised a maximum subscription share of 25 million US dollars, accounting for 13% of the current distribution.

Zhitongcaijing·11/16/2026 06:50:21
Listen to the news
The Zhitong Finance App learned that the biotech company Rezera (RZRA.US), which has developed an oral NLRP3 inflammatory inhibitor and has advanced the pipeline to phase III clinical trials, said on Thursday that it will suspend listing. The company previously filed for an IPO and plans to issue 16.7 million shares in the distribution range of $11-13 and raise $200 million. Pharmaceutical company GlaxoSmithKline (GSK.US), as a new investor and associated party, promised a maximum subscription share of 25 million US dollars, accounting for 13% of the current distribution.